73 related articles for article (PubMed ID: 21914463)
1. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
Bosotti R; Carpinelli P; Healy S; Locatelli G; Cappella P; Lanfrancone L; Calogero R; Moll J; Isacchi A
Gene; 2012 Feb; 494(2):202-8. PubMed ID: 21914463
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Steeghs N; Eskens FA; Gelderblom H; Verweij J; Nortier JW; Ouwerkerk J; van Noort C; Mariani M; Spinelli R; Carpinelli P; Laffranchi B; de Jonge MJ
J Clin Oncol; 2009 Oct; 27(30):5094-101. PubMed ID: 19770380
[TBL] [Abstract][Full Text] [Related]
3. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract][Full Text] [Related]
4. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Fraedrich K; Schrader J; Ittrich H; Keller G; Gontarewicz A; Matzat V; Kromminga A; Pace A; Moll J; Bläker M; Lohse AW; Hörsch D; Brümmendorf TH; Benten D
Clin Cancer Res; 2012 Sep; 18(17):4621-32. PubMed ID: 22753592
[TBL] [Abstract][Full Text] [Related]
5. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
6. Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Gontarewicz A; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():199-214. PubMed ID: 20072840
[TBL] [Abstract][Full Text] [Related]
7. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Steeghs N; Mathijssen RH; Wessels JA; de Graan AJ; van der Straaten T; Mariani M; Laffranchi B; Comis S; de Jonge MJ; Gelderblom H; Guchelaar HJ
Invest New Drugs; 2011 Oct; 29(5):953-62. PubMed ID: 20182906
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy.
Shang YY; Yu N; Xia L; Yu YY; Ma CM; Jiao YN; Li YF; Wang Y; Dang J; Li W
Drug Deliv Transl Res; 2020 Feb; 10(1):136-145. PubMed ID: 31625025
[TBL] [Abstract][Full Text] [Related]
9. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effect of Aurora kinase targeting in mesothelioma.
Crispi S; Fagliarone C; Biroccio A; D'Angelo C; Galati R; Sacchi A; Vincenzi B; Baldi A; Verdina A
Lung Cancer; 2010 Dec; 70(3):271-9. PubMed ID: 20371132
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways.
Li M; Jung A; Ganswindt U; Marini P; Friedl A; Daniel PT; Lauber K; Jendrossek V; Belka C
Biochem Pharmacol; 2010 Jan; 79(2):122-9. PubMed ID: 19686703
[TBL] [Abstract][Full Text] [Related]
12. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.
Tomita M; Mori N
Cancer Sci; 2010 May; 101(5):1204-11. PubMed ID: 20180813
[TBL] [Abstract][Full Text] [Related]
13. Development and biological evaluation of a novel aurora A kinase inhibitor.
Sardon T; Cottin T; Xu J; Giannis A; Vernos I
Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
[TBL] [Abstract][Full Text] [Related]
14. The effect of danusertib, an Aurora kinase inhibitor, onto the cytotoxicity, cell cycle and apoptosis in pancreatic ductal adenocarcinoma cells.
Kirbiyik IA; Ozcimen AA
J Cancer Res Ther; 2021; 17(6):1419-1424. PubMed ID: 34916372
[TBL] [Abstract][Full Text] [Related]
15. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase.
Yang H; Burke T; Dempsey J; Diaz B; Collins E; Toth J; Beckmann R; Ye X
FEBS Lett; 2005 Jun; 579(16):3385-91. PubMed ID: 15922328
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2.
Li J; Anderson MG; Tucker LA; Shen Y; Glaser KB; Shah OJ
Cell Death Differ; 2009 Mar; 16(3):498-511. PubMed ID: 19079141
[TBL] [Abstract][Full Text] [Related]
17. The anticancer agent prodigiosin induces p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway.
Soto-Cerrato V; Viñals F; Lambert JR; Pérez-Tomás R
Biochem Pharmacol; 2007 Nov; 74(9):1340-9. PubMed ID: 17765876
[TBL] [Abstract][Full Text] [Related]
18. ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Liu J; Hong J; Ahn KS; Go J; Han H; Park J; Kim D; Park H; Koh Y; Shin DY; Yoon SS
Leuk Lymphoma; 2019 Oct; 60(10):2532-2540. PubMed ID: 30947576
[TBL] [Abstract][Full Text] [Related]
19. Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A.
Liu HS; Ke CS; Cheng HC; Huang CY; Su CL
Mol Pharmacol; 2011 Oct; 80(4):638-46. PubMed ID: 21757545
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors.
Shi J; Xu G; Zhu W; Ye H; Yang S; Luo Y; Han J; Yang J; Li R; Wei Y; Chen L
Bioorg Med Chem Lett; 2010 Jul; 20(14):4273-8. PubMed ID: 20621733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
